Analysis of endocrine and metabolic characteristics in patients with polycystic ovary syndrome in Beijing

doi:10.3969/j.issn.1006-7795.2017.04.003

Abstract

Abstract: Objective To analyze the clinical characteristics, sex hormones and lipid metabolism in patients with polycystic ovary syndrome (PCOS) in Beijing. Methods Totally 142 untreated PCOS patients were enrolled, and 48 age-matched healthy women were included as control group. Patients were diagnosed and grouped using the Rotterdam 2003 criteria. Based on the National Institutes of Health (NIH) guidelines, patients with PCOS were classified as: subtype-1, androgen excess+ ovulatory dysfunction (AE+OD)(n=40); subtype-2, androgen excess + polycystic ovarian morphology (AE+PCO)(n=10); subtype-3, ovulatory dysfunction + polycystic ovarian morphology (OD+PCO) (n=32); subtype-4, androgen excess + ovulatory dysfunction + polycystic ovarian morphology (AE+OD+PCO)(n=60). The screening panel consisted of a physical examination, weight and height measurement, ultrasonography of the ovaries, and measurements of hormone, glucose, lipid, and insulin resistance. Besides, endocrine and metabolic parameters were measured in all patients. Results In the PCOS group, body mass index (BMI), waist and hip ratio (WHR), total testosterone (T), luteinizing hormone (LH), LH/follicle stimulating hormone(FSH) ratio were higher than that of the control group with statistically significant difference (P<0.05). Total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), triglycerides (TG), apolipoprotein B (ApoB) levels, fasting insulin (INS), homeostatic model assessment of insulin resistance (HOMA-IR) and the ratio of ApoB to ApoA were significantly higher than those in the control group (P<0.05). Meanwhile, high density lipoprotein-cholesterol (HDL-C) and apolipoprotein A (ApoA) level were lower than the control group with statistically significant difference (P<0.05). The BMI, WHR, T and LDL-C of subtype-1 were higher compared to subtype-3, and TC and LDL-C were higher than subtype-2; the BMI, T and LDL-C of 4 subtypes were higher than the three other subtypes and T, LH and LH/FSH were higher than subtype-2 with statistically significant difference (P<0.05). There was no significant difference between subtype-2 and subtype-3 (P>0.05). Conclusion The incidence of central obesity, lipid metabolism disorders, insulin resistance and hyperinsulinemia in PCOS patients in Beijing was significantly higher than that in healthy women. Among the four subtypes of PCOS patients, this phenomenon maybe is most significant in subtypes 1 and 4 subgroups with both ovulation abnormality and hyperandrogenism, while subtypes with normal menstrual cycle or non-hyperandrogenic have more moderate metabolic changes, Distinction of the four subtypes should be made during clinical treatment and targeted therapy should be applied correspondingly.

Key words: polycystic ovary syndrome, subtype, lipid metabolic, abdominal obesity, insulin resistance

CLC Number:

R711.75

Yin Dongmei, Ruan Xiangyan, Zhao Yue, Alfred O. Mueck. Analysis of endocrine and metabolic characteristics in patients with polycystic ovary syndrome in Beijing[J]. Journal of Capital Medical University, 2017, 38(4): 498-503.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.04.003

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I4/498

References

[1] Li R, Zhang Q, Yang D, et al.Prevalence of polycystic ovary syndrome in women in China: a large community-based study [J]. Hum Reprod,2013, 28 (9):2562-2569.
[2] Palomba S, Santagni S, Falbo A, et al. Complications and challenges associated with polycystic ovary syndrome: current perspectives [J]. Int J Womens Health,2015, 31 (7):745-763.
[3] Chan J L, Kar S, Vanky E, et al. Racial and ethnic differences in the prevalence of metabolic syndrome and its components of metabolic syndrome in women with polycystic ovary syndrome (PCOS): a regional cross-sectional study [J]. Am J Obstet Gynecol, 2017, Epub of print.
[4] Rotterdam ESHRE/ASRM-sponsored. PCOS consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome [J].Hum Reprod,2004,19:41-47.
[5] National Institute of Health. Evidence-based methodology workshop on polycystic ovary syndrome［EB/OL］. ［2017-06-05］. https://prevention.nih.gov/docs/programs/pcos/finelreport.pdf.
[6] Kumar A N, Naidu J N, Satyanarayana U, et al. Metabolic and endocrine characteristics of Indian women with polycystic ovary syndrome [J].Int J Fertil Steril, 2016,10 (1):22-28.
[7] Hsu M I. Clinical characteristics in Taiwanese women with polycystic ovary syndrome [J].Clin Exp Reprod Med,2015,42(3):86-93.
[8] Kumar A N, Naidu J N, Satyanarayana U,et al. Metabolic and endocrine characteristics of indian women with polycystic ovary syndrome [J].Int J Fertil Steril,2016,10(1):22-28.
[9] Ganie M A, Marwaha R K, Dhingra A, et al. Observation of phenotypic variation among Indian women with polycystic ovary syndrome (PCOS) from Delhi and Srinagar [J]. Gynecol Endocrinol,2016,15:1-5.
[10] Dilbaz B, Ozkaya E, Cinar M, et al.Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes[J].Endocrine,2011,39(3):272-277.
[11] 赵越, 阮祥燕, 崔亚美,等. 不同亚型的多囊卵巢综合征病人临床及实验室指标特征的研究 [J].首都医科大学学报,2015,36(4):567-572.
[12] Li H, Li L, Gu J, et al. Should all women with Polycystic ovary syndrome Be screened for metabolic parameters? A hospital-based observational study[J].PLoS One,2016,30,11(11):e0167036.
[13] Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis [J]. Hum Reprod,2016,31(12):2841-2855.
[14] 陈子江,张以文,刘嘉茵,等.多囊卵巢综合征诊断-中华人民共和国卫生行业标准[J]. 中华妇产科杂志, 2012, 47(1): 74-75.
[15] Rizzo M, Berneis K, Hersberger M, et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndromephenotype [J].Hum Reprod, 2009,24(9):2286-2292.
[16] Mario F M, Graff S K, Spritzer P M. Adiposity indexesas phenotype-specific Markers of preclinical metabolic alterations and cardiovascular risk in polycystic ovary syndrome: a cross-sectional study [J].Exp Clin Endocrinol Diabetes, 2017, 125(5):307-315.
[17] Tziomalos K. Cardiovascular risk in the different phenotypes of polycystic ovary syndrome [J].Curr Pharm Des 2016,22(36):5547-5553.
[18] Pinola P, Puukka K, Piltonen T T, et al. Normo-and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life[J].Fertil Steril, 2017,107(3):788-795.
[19] Çelik E, Türkçüog lu I, Ata B. Metabolic and carbohydrate characteristics of different phenotypes of polycystic ovary syndrome [J].J Turk Ger Gynecol Assoc, 2016,17(4):201-208.
[20] Pau C T, Mosbruger T, Saxena R,et al. Phenotype and tissue expression as a function of genetic risk in polycystic ovary syndrome[J]. PLoS One,2017,12(1):e0168870.